Cracking the Code: A Pure Global Guide to Clinical Evidence for AI Medical Devices in Indonesia and the Broader ASEAN Market

This episode of ASEAN MedTech Insights dives deep into the specific clinical evidence requirements for AI-powered medical devices seeking market approval in Indonesia. We uncover why a standard CE mark or FDA clearance is often not enough and explore the nuances of demonstrating your product's efficacy for the diverse Indonesian population. Imagine a MedTech company with a breakthrough AI diagnostic tool, already approved in the United States. They anticipate a quick entry into the large Indonesian market but are met with unexpected questions and delays from regulators. The core problem is that their clinical trials were conducted on a different demographic, and they now face the costly and time-consuming challenge of proving their algorithm works for Indonesian patients. This episode provides a roadmap to avoid that exact scenario. Key questions answered in this episode: - Why is simply having a CE mark or FDA approval not enough for AI device registration in Indonesia? - What specific questions will the Indonesian Ministry of Health ask about your AI model's training data? - How can you proactively demonstrate your algorithm's relevance to the diverse Indonesian population? - What is a "local validation study," and when is it absolutely necessary? - How does Indonesia's risk classification system impact the clinical data required for AI software? - What is the most common mistake companies make when preparing their Clinical Evaluation Report for Indonesia? - Are there strategies to justify using foreign clinical data without conducting a new, expensive local study? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology (MedTech) and In-Vitro Diagnostic (IVD) companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at [email protected] or visit us at https://pureglobal.com.